AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals
By Michael Hennessey
AstraZeneca reported positive results from its Phase 3 trial of Tezspire in patients with eosinophilic esophagitis, an inflammatory disorder of the esophagus.
The Cambridge-based pharmaceutical company said Thursday that the drug demonstrated improvements across co-primary and all key secondary endpoints at week 24 of the trial, which were sustained to week 52.
The co-primary endpoints were histologic remission and the frequency and severity of dysphagia--or difficulty swallowing--compared with the placebo. The safety profile of the drug was generally consistent with its approved indications, AstraZeneca added.
The drug is being developed in collaboration with U.S. biotechnology company Amgen.
Tezspire is currently approved for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps in the U.S., EU, China and Japan.
Write to Michael Hennessey at michael.hennessey@wsj.com
(END) Dow Jones Newswires
August 27, 2026 03:07 ET (07:07 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States